Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

H2020-FTI Pilot. Búsqueda de socios clínicos para validar un nuevo dispositivo de diagnóstico in vitro

Resumen

Tipo:
Búsqueda de socios
Referencia:
RDFR20160826001
Publicado:
07/09/2016
Caducidad:
07/09/2017
Resumen:
Un consorcio francés está trabajando en la validación de un dispositivo médico de diagnóstico en una cohorte independiente de pacientes con cáncer pancreático sometidos a un tratamiento con gemcitabina de primera línea. La propuesta será presentada a la acción piloto del programa Horizon 2020 Fast Track to Innovation. El consorcio busca clínicas y hospitales interesados en utilizar el diagnóstico en la investigación traslacional del cáncer pancreático. La fecha límite de la convocatoria es el 25 de octubre de 2016 y el plazo para presentar expresiones de interés finaliza el 1 de octubre.

Details

Tittle:
A H2020-FTI Pilot consortium is looking for clinical partners to validate a new in vitro diagnostic device
Summary:
A French-based consortium is building up to validate a diagnostic medical device on an independent cohort of pancreatic cancer patients under a first-line gemcitabine treatment. The project proposal will be submitted to Horizon 2020 Fast Track to Innovation Pilot call.
They are looking for clinics and hospitals interested in the use of (companion) diagnostics for translational research focused on (pancreatic) cancer.
Description:
Pancreatic cancer represents 220,000 new cases each year and 140,000 cancer related deaths. The median survival of pancreatic cancer patients is around 3 to 6 months. Gemcitabine was the standard first-line treatment. Today, other treatments are also used like folfirinox or gemcitabine plus erlotinib or gemcitabine plus nab-paclitaxel, but the improvements in median survival duration compared to sole gemcitabine are modest. It is mandatory to develop new therapeutic strategies for this pathology with high unmet medical needs.

A French biotechnology company specialized in the development of innovative diagnostics is building a consortium to validate a new diagnostic test dedicated to pancreatic cancer patients treated with gemcitabine.

This In-Vitro Diagnostic (IVD) test is based on a gene blood-signature. This new IVD test is easy to use because based on a blood sample and quantitative real-time Polymerase Chain Reaction (PCR) assay. The result determines the sub-population of patients more sensitive to gemcitabine treatment. This test combined to gemcitabine improves by twice the median survival rates of the sensitive responder patients.

Hence, for the patients less or not sensitive to gemcitabine, other treatments can be directly used. This innovative IVD test could play a major role in the personalized medicine strategy.

The consortium currently consists of SMEs and hospitals. Its members are looking for clinics and hospitals to complete the group and to validate in clinics this new IVD.

The project proposals will be submitted to Horizon 2020 under the FTIPilots-01-2016: Fast track to innovation Pilot.

Deadline for expression of interest: 1st October 2016
Deadline for the call: 25 October 2016
Advantages and Innovations:
- A non-invasive assay
- A new blood-based signature, based on a high throughput analysis of Next-Generation Sequencing (NGS)/Sequencing data using a proprietary genomics platform (Big Data system dedicated to Biomarker discovery)
- An IVD test combined to gemcitabine treatment improving by twice the median survival rates of the sensitive pancreatic cancer patients
Stage of Development:
Available for demonstration
Technical Specification or Expertise Sought:
Cancer, translational medicine, Gemcitabine, pancreatic cancer
IPR Status:
Patent(s) applied for but not yet granted

Partner sought

Partner Sought:
Clinics and hospitals interested in translational medicine, in patient cohort inclusion and, in Blood biobanking for future collaborations
Type of Partnership Considered:
RDR

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Dissemination

Programme-call